CF
VYGR icon

Corebridge Financial’s Voyager Therapeutics VYGR Stock Holding History

Corebridge Financial’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,537
Closed -$76.2K – 2753
2025
Q1 		$76.2K Sell
22,537
-333
-1% -$1.56K ﹤0.01% 2578
2024
Q4 		$130K Sell
22,870
-1,727
-7% -$11.1K ﹤0.01% 2428
2024
Q3 		$144K Sell
24,597
-152
-0.6% -$1.1K ﹤0.01% 2412
2024
Q2 		$196K Buy
+24,749
New +$207K ﹤0.01% 2210

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's VYGR Position: Q2 2025 in Review

Corebridge Financial sold out of Voyager Therapeutics (VYGR) in Q2 2025, closing a stake of 22,537 shares — an estimated $76.2K sold.

Corebridge Financial first reported a position in VYGR in Q2 2024 and held it in 4 quarters. The position peaked at $196K in Q2 2024. 112 funds tracked by Wall St. Rank hold VYGR as of Q2 2025.

  • Corebridge Financial reported no remaining Voyager Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 22,537 Voyager Therapeutics shares in Q2 2025, an estimated $76.2K.
  • Corebridge Financial first reported a position in Voyager Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Voyager Therapeutics position peaked at $196K in Q2 2024.
  • 112 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.